Novotech, the Asia Pacific centered biotech specialist CRO, will attend JPM 2023 and experts from the US and Asia Pacific teams are available for meetings via BIO Partnering.

Novotech CEO Dr. John Moller is presenting at JPM on 11 January 2023. Dr. Moller has been invited to share Novotech’s growth and global expansion program.

Book a meeting with the Novotech team here

Novotech can share the benefits of Asia Pacific for expedited clinical trials where biotechs can access Novotech’s vast patient populations, local regulatory knowledge, extensive site and KOL network, and reputation for data quality.

Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.

The latest industry research publication by GlobalData and Novotech found almost 50% of new trials have sites in Asia Pacific.

According to the new publication titled State of the Global Biotech Landscape: Where the Opportunities Lie, demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific.

The data shows almost 12,900 of the new trials had sites in Asia Pacific.

Download the report here

The report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region. 

Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.

Frost & Sullivan said:

“Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement.

Novotech addresses the global drug development market’s unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation.

From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients.”
 

Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals.

The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway.

Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.

Download whitepaper here 

Novotech has also recently been benchmarked as a top 10 CRO among the world’s leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. 

Media contact

데이빗 제임스 (David James)

언론 연락처

노보텍 헬스 홀딩스(Novotech Health Holdings)소개

노보텍 헬스 홀딩스 유한회사(Novotech Health Holdings Pte. Ltd., 이하 "노보텍")는 아시아 태평양 지역을 선도하는 바이오테크 전문 CRO로써, 노보텍과 PPC라는 두 개의 영업 브랜드로 구성되어 있다. 노보텍은 약제 개발 컨설팅과 임상 개발 서비스를 제공하는 통합 연구소와 임상1상 시설을 갖추고 있는 CRO이다. 이는 임상 전 과정 및 폭넓은 치료 분야에 걸친 약 4,000여회의 임상실험 성공에 중추적인 역할을 해왔다. 노보텍은 아시아를 비롯해 전 세계 바이오 제약사 고객들에게 임상 실험 서비스를 제공하는데 있어서 우위를 점하고 있다. 좀 더 자세한 내용은 https://novotech-cro.com/kr/contact 를 통해 확인할 수 있다.

기타 관련 콘텐츠